Skip to main content
Premium Trial:

Request an Annual Quote

NIH Grants HelixBind $3M for Early Detection Lyme Test

NEW YORK – Infectious disease diagnostic company HelixBind announced Thursday it has received $3 million from the National Institutes of Health to evaluate the company's early detection test for Lyme disease. 

The money is to support clinical studies evaluating the test, which detects DNA from tick-borne bacteria Borrelia burgdorferi directly from the patient's blood. The test has a limit of detection of less than 1 cell per milliliter and can detect the infection at "the earliest timepoint," the company said in a statement.

HelixBind CEO Alon Singer said diagnosis of Lyme disease is currently limited by the sensitivity of existing tests, so "this new grant from the NIH will help us demonstrate whether the improved sensitivity of our test can improve diagnosis." 

The firm has clinical studies planned for 2021's tick season and is looking to add additional clinical partners, it said.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.